Summary
Edwards Lifesciences Corporation (EW) has filed an 8-K report on December 5, 2006, detailing significant operational changes driven by a strategic realignment and the discontinuation of its Atrial Fibrillation Program, specifically the Optiwave 980 Cardiac Laser Ablation System. This decision is expected to result in a pre-tax charge of approximately $16 million in the fourth quarter of 2006. The charge comprises $9 million in non-cash asset write-offs (including intangibles, inventory, and fixed assets) and $7 million in employee severance and benefit costs, affecting approximately 70 full-time positions, primarily in the U.S. This move signals a focus on core strategic opportunities, shifting resources away from underperforming product lines. Investors should note that sales from the discontinued Atrial Fibrillation Program were minimal, contributing less than $1 million in the first nine months of 2006. The company views this as a necessary step to streamline operations and enhance focus on its key growth areas within the cardiovascular device market.
Key Highlights
- 1Edwards Lifesciences is discontinuing its Atrial Fibrillation Program, including the Optiwave 980 Cardiac Laser Ablation System.
- 2The company is realigning resources to focus on key strategic opportunities.
- 3Approximately 70 full-time positions will be eliminated, primarily in the U.S.
- 4A pre-tax charge of approximately $16 million is expected in Q4 2006.
- 5The charge includes $9 million in non-cash asset write-offs (intangibles, inventory, fixed assets).
- 6Employee severance and benefit costs are estimated at $7 million.
- 7Sales from the discontinued program were less than $1 million for the nine months ended September 30, 2006.